Compare AIN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIN | NVAX |
|---|---|---|
| Founded | 1895 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1994 | 1996 |
| Metric | AIN | NVAX |
|---|---|---|
| Price | $52.94 | $7.98 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $60.25 | $11.33 |
| AVG Volume (30 Days) | 242.7K | ★ 3.6M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | $1,054,132,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.98 |
| Revenue Growth | 7.29 | ★ 64.69 |
| 52 Week Low | $41.15 | $5.01 |
| 52 Week High | $73.00 | $11.85 |
| Indicator | AIN | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 36.31 |
| Support Level | $51.74 | $6.35 |
| Resistance Level | $53.88 | $8.45 |
| Average True Range (ATR) | 1.73 | 0.53 |
| MACD | 0.20 | -0.25 |
| Stochastic Oscillator | 66.19 | 12.15 |
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.